Antibody Fragments Market Analysis

Antibody Fragments Market Analysis

To get key market trends

  Download Free Sample

Based on specificity, the market is segmented into monoclonal antibodies and polyclonal antibodies. The monoclonal antibody segment is further bifurcated into Praxbind (Idarucizumab), Ranibizumab (Lucentis), Certolizumab pegol (Cimzia), Iodine (I 311) Metuximab/Licartin, Beovu (Brolucizumab-dbll), Cablivi (Caplacizumab-yhdp), and Blinatumomab. Similarly, the polyclonal antibody segment is further bifurcated into CroFab, Anavip, Anascorp, Botulism Antitoxin Heptavalent, Digibind, and Digifab. The monoclonal antibody segment of the market is forecasted to reach USD 7.5 billion by 2032.
 

• The dominance of the monoclonal antibody segment is due to the specificity of monoclonal antibody fragments. These fragments retain the high specificity of their parent antibodies, allowing precise binding to specific antigens or receptors on diseased cells. This precision makes them highly effective in targeted therapies, particularly in oncology and autoimmune diseases.
   
• Additionally, monoclonal antibody fragments can be engineered for various improvements, such as increased binding affinity, stability, or circulatory half-life. These advancements enable scientists to fine-tune fragments for optimal therapeutic performance, driving the higher adoption of monoclonal antibody fragments globally.
   

Based on type, the antibody fragments market is bifurcated into FAB, scFv, sdAb, and other types. The scFv segment accounted for USD 2.3 billion in 2023.
 

• The leading share of the scFv segment can be attributed to the increasing incidence of cancer. According to the World Health Organization, projections indicate over 35 million new cancer cases by 2050, marking a 77% rise from the estimated 20 million cases in 2022. scFvs are finding increasing applications in targeted cancer therapeutics. The smaller size of scFvs enhances their ability to access difficult-to-reach targets, such as tumor cells deep within tissue or in microenvironments that full-sized antibodies might not penetrate effectively.
   
• scFvs are also finding increasing adoption in CAR-T cell therapies, a leading area in cancer immunotherapy. In CAR-T therapy, scFvs direct the patient’s T cells to recognize and destroy cancer cells. Thus, with the growing adoption of CAR-T cell therapies, the demand for scFvs is expected to increase during the forecast period.

Based on application, the antibody fragments market is bifurcated into cancer, immunodeficiency, and other applications. The cancer segment accounted for USD 3.8 billion in 2023.
 

• The growing burden of cancer has led to increased demand for effective treatments, driving innovation in areas like antibody fragment-based therapies. According to the World Health Organization, roughly 20% of individuals will be diagnosed with cancer at some point in their lives, with mortality rates standing at about 11% for men and 8% for women in 2022.
   
• Additionally, the proven efficacy and safety of antibody fragment-based therapies in cancer treatment are driving global demand. Antibody fragments, including scFv and FAB fragments, retain the ability to specifically bind to tumor-associated antigens, making them highly effective in targeting cancer cells without affecting normal, healthy cells.
   
• Moreover, antibody fragments can be customized to target specific cancer mutations. Hence, the increasing adoption of personalized medicine for cancer treatment is driving the demand for antibody fragments, contributing to revenue growth in the segment.
   

The growth of the antibody fragments market in the U.S. is projected to reach USD 4 billion by 2032.
 

• The region has one of the highest cancer prevalence rates globally. For instance, according to the American Cancer Society, about 1.9 million new cancer cases were diagnosed in 2022. This large patient population drives demand for cancer therapies, further increasing the demand for antibody fragments in the country.
   
• Furthermore, the country is home to a large number of prominent biotechnology and pharmaceutical companies, including Amgen, Genentech, Pfizer, and Bristol-Myers Squibb. These industry leaders spearhead the development and commercialization of biologics, including antibody fragments, aiding revenue growth in the U.S. market.
   
• Additionally, favorable regulatory policies and increasing approvals for antibody therapies by the U.S. FDA are also supporting market growth. In 2023, the U.S. FDA granted approval to 55 new molecular entities, including 12 therapeutic antibodies.
   

The antibody fragments market in the UK is expected to experience significant growth from 2024 to 2032. Several factors contribute to the UK's leadership in the market, including its strong biotechnology sector, supportive regulatory environment, and vibrant research landscape.
 

• The UK biotechnology market is recognized for its innovative strategies and pioneering research, positioning it at the forefront of developing novel antibody fragment-based therapies. According to Statista, the number of enterprises in biotechnology research surged from about 174 to 1,454 between 2008 and 2022.
   
• Moreover, the UK is a hub for medical research and innovation. Numerous universities and research institutions, such as the William Harvey Research Institute (WHRI) and Antibody-Based Medicines Research Group (ABMRG), focus on advancing targeted therapies for cancer and immunodeficiency diseases. This research contributes to the development of more accurate, efficient, and user-friendly antibody fragment-based therapies, driving market growth.
   

Japan’s antibody fragments market is anticipated to witness lucrative growth between 2024 and 2032.
 

• The Japanese government and private sector invest heavily in R&D, particularly in biotechnology and pharmaceuticals. This commitment to innovation supports the development of cutting-edge therapies, including antibody fragments.
   
• For instance, the Tokyo Metropolitan Government’s Blockbuster TOKYO program provides funding for firms working on drug design and medical startups. Such favorable initiatives and government support drive antibody-based research in Japan, further aiding market growth.
   
• Additionally, Japan's high prevalence of cancer and chronic diseases drives strong demand for effective therapies. As a result, there is a growing exploration of antibody fragments for their potential in targeted cancer treatments, contributing to revenue growth in Japan’s market.
   

The antibody fragments market in Saudi Arabia is expected to experience significant growth from 2024 to 2032.
 

• Saudi Arabia is investing significantly in biotechnology research, contributing to rapid growth in R&D for antibody fragment-based targeted therapies. The country has launched its National Biotech Strategy, aiming to lead the MENA biotech sector by 2030 and establish itself as a global biotech hub by 2040. This initiative is projected to have a cumulative impact of USD 34.6 billion.